Cytek Biosciences (NASDAQ:CTKB - Get Free Report) is expected to announce its Q2 2025 earnings results after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $46.03 million for the quarter. Cytek Biosciences has set its FY 2025 guidance at EPS.
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.05). The firm had revenue of $41.46 million during the quarter, compared to analysts' expectations of $43.18 million. Cytek Biosciences had a negative net margin of 5.71% and a negative return on equity of 2.90%.
Cytek Biosciences Price Performance
Shares of CTKB stock traded up $0.04 on Friday, hitting $3.64. The stock had a trading volume of 1,538,192 shares, compared to its average volume of 933,205. The firm has a market capitalization of $461.04 million, a P/E ratio of -40.44 and a beta of 1.34. Cytek Biosciences has a 1 year low of $2.37 and a 1 year high of $7.63. The company's 50 day moving average price is $3.29 and its 200-day moving average price is $3.95.
Analysts Set New Price Targets
Several research analysts recently commented on CTKB shares. TD Cowen cut Cytek Biosciences from a "buy" rating to a "hold" rating and set a $4.00 target price for the company. in a research note on Friday, May 9th. Morgan Stanley lowered their target price on Cytek Biosciences from $9.00 to $7.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 28th. Finally, The Goldman Sachs Group lowered their target price on Cytek Biosciences from $3.50 to $3.00 and set a "sell" rating for the company in a research note on Monday, May 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Cytek Biosciences currently has a consensus rating of "Hold" and a consensus target price of $5.60.
Get Our Latest Report on CTKB
Insider Activity
In other Cytek Biosciences news, CFO William D. Mccombe acquired 35,000 shares of the stock in a transaction dated Monday, June 2nd. The stock was acquired at an average cost of $2.78 per share, with a total value of $97,300.00. Following the transaction, the chief financial officer owned 55,746 shares in the company, valued at $154,973.88. The trade was a 168.71% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.33% of the company's stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the business. Strs Ohio acquired a new position in shares of Cytek Biosciences during the 1st quarter worth about $105,000. Acadian Asset Management LLC acquired a new position in shares of Cytek Biosciences during the 1st quarter worth about $162,000. Jane Street Group LLC boosted its position in shares of Cytek Biosciences by 412.2% during the 1st quarter. Jane Street Group LLC now owns 344,169 shares of the company's stock worth $1,380,000 after acquiring an additional 276,972 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Cytek Biosciences by 394.4% during the 1st quarter. AQR Capital Management LLC now owns 653,277 shares of the company's stock worth $2,620,000 after acquiring an additional 521,135 shares in the last quarter. 69.46% of the stock is owned by institutional investors and hedge funds.
About Cytek Biosciences
(
Get Free Report)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
See Also
Before you consider Cytek Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytek Biosciences wasn't on the list.
While Cytek Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access